@rupsha Ovarian cancer is the most lethal gynecological cancer of women with a 5-year survival rate of only 47%. This is mainly due to the fact that up to 59% of ovarian cancers are detected at advanced stages, for which survival is 29%. Cytoreductive surgery in combination with platinum- and taxane-based chemotherapy represents the gold standard for first-line therapy in ovarian cancer, and several studies have shown that gross residual disease correlates with survival. Two randomized phase III trials have been carried out adding bevacizumab to first-line chemotherapy and maintenance. Both studies suggested that the use of bevacizumab prolongs the median progression free survival in patients with advanced epithelial cancer. The consistency in the data across these trials, along with a prolific safety database, led to approval of bevacizumab for first-line maintenance in Europe and US
R